Jazz Pharmaceuticals (NASDAQ:JAZZ) Earns Buy Rating from HC Wainwright

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $200.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 57.89% from the company’s previous close.

Several other research analysts have also recently weighed in on JAZZ. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Piper Sandler restated an “overweight” rating and issued a $163.00 target price (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research report on Thursday. Cantor Fitzgerald restated an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Needham & Company LLC reissued a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday. Finally, Robert W. Baird increased their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research note on Monday, November 18th. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $175.33.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $126.67 on Friday. The firm has a market capitalization of $7.66 billion, a PE ratio of 17.84, a price-to-earnings-growth ratio of 1.05 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company’s fifty day moving average price is $113.65 and its 200-day moving average price is $110.73. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $134.17.

Insiders Place Their Bets

In related news, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. This trade represents a 8.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,110 shares of company stock worth $720,160 over the last 90 days. Corporate insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Coldstream Capital Management Inc. lifted its holdings in Jazz Pharmaceuticals by 7.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock worth $259,000 after buying an additional 165 shares during the last quarter. MidWestOne Financial Group Inc. lifted its stake in Jazz Pharmaceuticals by 5.4% during the third quarter. MidWestOne Financial Group Inc. now owns 22,063 shares of the specialty pharmaceutical company’s stock worth $2,458,000 after purchasing an additional 1,134 shares during the last quarter. Barclays PLC boosted its holdings in Jazz Pharmaceuticals by 19.1% in the third quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company’s stock valued at $4,369,000 after purchasing an additional 6,289 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in Jazz Pharmaceuticals in the third quarter valued at approximately $2,491,000. Finally, XTX Topco Ltd raised its holdings in Jazz Pharmaceuticals by 57.5% during the third quarter. XTX Topco Ltd now owns 11,631 shares of the specialty pharmaceutical company’s stock worth $1,296,000 after purchasing an additional 4,245 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.